Autolus Therapeutics plc - Special Call Transcript
Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics ASH AUTO1 and AUTO3 Data Update. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Dr. Lucinda Crabtree, Vice President, Investor Relations. Please go ahead.
Thank you. Good morning or good afternoon, everyone, and thank you for taking part in today's call on the ASH AUTO1 and AUTO3 Data Update. I am Lucinda Crabtree, Vice President of Investor Relations.
With me today are Dr. Christian Itin, our Chairman and Chief Executive Officer; Dr. Robert Chen, our AUTO3 and lymphoma program lead; Dr. Nushmia Khokhar, our Head of Clinical Development; Brent Rice, our Chief Commercial Officer; Dr. Martin Pulé, our Chief Scientific Officer; and Andrew Oakley, our Chief Financial Officer.
Before we begin, I would like to remind you that during today's call, our discussion will contain forward-looking statements. All statements,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
